Volume 112, Nº 4, April 2019
DOI: http://www.dx.doi.org/10.5935/abc.20190029
REVIEW ARTICLE
PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice
Filipe Ferrari
Ricardo Stein
Marcelo Trotte Motta
Emilio Hideyuki Moriguchi
Dr. Filipe Ferrari
Figure 1 – Mechanisms of PCSK9 involvement in LDL metabolism.
Keywords: Cardiovascular Diseases/physiopathology; Coronary Artery Disease/mortality; Proprotein Convertase 9; Cholesterol, LDL; Lipoproteins; Anticholesteromic Agents.